ERBB2 and breast carcinoma: On these premises, a meta-analysis was carried out in two parts for pT1a-bN0M0 breast cancer patients: one was to evaluate the prognostic profiles of intrinsic subtypes; the other to explore the survival benefits of adjuvant trastuzuamb in HER2-positive phenotype.